1. Colombel, JF, Sandborn, WJ, Rutgeerts, P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52–65.
Google Scholar | Crossref | Medline | ISI2. Sandborn, WJ, van Assche, G, Reinisch, W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257–265.
Google Scholar | Crossref | Medline | ISI3. Sandborn, WJ, Colombel, JF, Schreiber, S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn’s disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141–151.
Google Scholar | Crossref | Medline4. Wolf, D, D’Haens, G, Sandborn, WJ, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 2014; 40: 486–497.
Google Scholar | Medline5. US Prescribing Information , https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s415lbl.pdf (accessed 12 June 2021).
Google Scholar6. EU SmPC , https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf (accessed 12 June 2021).
Google Scholar7. Sylwestrzak, G, Liu, J, Stephenson, JJ, et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits 2014; 7: 71–81.
Google Scholar | Medline8. Overton, PM, Shalet, N, Somers, F, et al. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence 2021; 15: 811–834.
Google Scholar | Crossref | Medline9. von Elm, E, Altman, DG, Egger, M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.
Google Scholar | Crossref | Medline | ISI10. Atkinson, MJ, Sinha, A, Hass, SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
Google Scholar | Crossref | Medline11. Jubert-Esteve, E, Del Pozo-Hernando, LJ, Izquierdo-Herce, N, et al. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study. Actas Dermosifiliogr 2015; 106: 644–650.
Google Scholar | Crossref | Medline12. EuroQol Group . EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.
Google Scholar | Crossref | Medline | ISI13. Alcalá, MJ, Casellas, F, Fontanet, G, et al. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 383–391.
Google Scholar | Crossref | Medline | ISI14. Casellas, F, Alcalá, MJ, Prieto, L, et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99: 457–461.
Google Scholar | Crossref | Medline15. Motoya, S, Watanabe, M, Wallace, K, et al. Efficacy and safety of dose escalation to adalimumab 80 mg every other week in Japanese patients with Crohn’s disease who lost response to maintenance therapy. Inflamm Intest Dis 2018; 2: 228–235.
Google Scholar | Crossref | Medline16. Paul, S, Williet, N, Nancey, S, et al. No difference of adalimumab pharmacokinetics when dosed at 40 mg every week or 80 mg every other week in IBD patients in clinical remission after adalimumab dose intensification. Dig Dis Sci 2021; 66: 2744–2749.
Google Scholar | Crossref | Medline17. Huynh, TK, Ostergaard, A, Egsmose, C, et al. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence 2014; 8: 93–99.
Google Scholar | Medline18. Ferreiro-Iglesias, R, Jardi, A, Quiroga, A, et al. P553 Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week. J Crohns Colitis 2019; 13: S390–S391.
Google Scholar | Crossref